Serif Biomedicines has announced preclinical data showing the potential of its Modified DNA as a new class of genetic medicines. Results from non-human primates, announced at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2026, suggest Modified DNA could overcome barriers of innate immune… Read More
An in vivo therapy being developed to treat X-linked chronic granulomatous disease (X-CGD) has shown positive early results. EN-374, developed by cellular engineering company Ensoma, has demonstrated tolerability in the first participant being evaluated in the Phase I/II trial. The therapy is a first-in-class in vivo haematopoietic stem cell… Read More
Biotechnology company Coave Therapeutics is set to unveil its OneAAV universal capsid at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. The company will deliver two oral presentations and present two posters at the event, being held 11 – 15 May in Boston, US, showing data… Read More
The International Society for Cell & Gene Therapy (ISCT)’s conference took place from 7-10 May, just before the American Society of Gene & Cell Therapy (ASGCT)’s conference from 13-17 May, both in New Orleans. Here, industry experts provided DDW’s Megan Thomas with insight from the events. Allogeneic cell therapies Lindsay… Read More
There have been a number of key events in the drug discovery community’s diary in 2024 to date, from AACR 2024 and LSX Congress 2024 to SLAS 2024 in Boston and… Read More
